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53Atrial ﬁbrillation (AF) is associated with an increased risk of
stroke and cardiovascular mortality (1). Treatment with oral
anticoagulation is recommended for prevention of stroke if the
protective effects outweigh the risk of severe bleeding (2). The
availability of new oral anticoagulants that provide a further
reduction in the risk of stroke and mortality and a lower risk of
intracranial bleeding might widen the indications for oral
anticoagulation because of a better balance between beneﬁts
and risks as comparedwithwarfarin (3,4).Over the past decade,
the risk of stroke in patients with AF has been estimated by the
CHADS2 (congestive heart failure, hypertension, 75 years of
age and older, diabetes mellitus, previous stroke or transient
ischemic attack) risk score, integrating the risk factors of
congestive heart failure, hypertension, 75 years of age, dia-
betes mellitus, and previous stroke (2) (5). The score classi-
ﬁcation has recently been expanded by adding the risk factors of
65 to 74 years of age, female sex, and vascular disease, now
featured in the CHA2DS2VASc (congestive heart failure,
hypertension, 75 years of age and older, diabetes mellitus,
previous stroke or transient ischemic attack, vascular disease, 65
to 74 years of age, female) score (6). In addition, the use of the
complementary HAS-BLED (hypertension, abnormal renal/
liver function, stroke, bleeding history or predisposition, labile
international normalized ratio, elderly, drugs/alcohol
concomitantly) score for evaluation of bleeding risk has been
recommended (2). Currently, the occurrence of at least 1
CHADS2 risk factor or a score of 2 according to CHA2DS2-
VASc is considered an indication for oral anticoagulation for
prevention of stroke in patients with AF.
It was recently proposed that the addition of bio-
marker information (i.e., troponin and N-terminal pro-brain
natriuretic peptide levels) might improve the discriminatory
information concerning ischemic events, mortality, and
bleeding in patients with AF treated with anticoagulation
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allowing detection and measure-
ment of troponin levels with high
levels of precision in almost all
subjects (8,9). Information on
the high-sensitivity troponin T
(hs-TnT) level has improved the
prognostic information not only
in patients with chest pain and
acute coronary syndromes but also
in patients with conditions such as
congestive heart failure and stable
atherosclerotic disease and even
in apparently healthy elderly subjects (10–16). In the
ARISTOTLE (Apixaban for the Prevention of Stroke in
Subjects With Atrial Fibrillation) trial, we obtained plasma
samples for central biomarker analyses from 14,897 of 18,201
patients (4,17). In this pre-speciﬁed substudy, we assessed the
associations between hs-TnT levels at baseline and clinical
outcomes after adjusting for established cardiovascular risk
factors. We also compared the prognostic information with
that of the CHA2DS2VASc score and evaluated the outcomes
with apixaban as compared with warfarin in relation to levels
of hs-TnT.
Methods
The ARISTOTLE trial. The details of the ARISTOTLE
trial have been published previously (17). Brieﬂy, ARIS-
TOTLE was a double-blind, double-dummy, randomized
clinical trial that enrolled 18,201 patients with AF and at
least one CHADS2 risk factor for stroke or systemic embo-
lism. Patients were randomized to treatment with warfarin
(n ¼ 9,081) or apixaban (n ¼ 9,120). The primary endpoint
was stroke or systemic embolism. Bleeding was classiﬁed
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54Haemostasis criteria. The median length of follow-up was
1.9 years in the biomarker substudy.
Endpoints and clinical risk classiﬁcation. The endpoints
in this study included stroke or systemic embolism, is-
chemic stroke and systemic embolism, hemorrhagic stroke,
myocardial infarction, all-cause mortality, cardiac death
(excluding bleeding and other noncardiac causes), and major
bleeding based on the International Society on Thrombosis
and Haemostasis criteria; composites included stroke or
systemic embolism, total death or cardiac death, and myo-
cardial infarction. A blinded clinical events committee ad-
judicated all endpoints using pre-speciﬁed criteria (17).
CHADS2 and CHA2DS2VASc scores were calculated for
each patient based on the sum of the corresponding risk
factors present at randomization. Patients were classiﬁed by
CHADS2 (low risk: 0 to 1; medium risk: 2; high risk: 3)
and CHA2DS2VASc scores (very low risk: 0 to 1; low risk:
2; medium risk: 3; elevated risk: 4; high risk: 5). Outcomes
in relation to HAS-BLED scores were also evaluated as
a sensitivity analysis.
Biochemical methods. All patients were required to
provide plasma samples at randomization, and the samples
were frozen in aliquots and stored at –70C until analyzed
centrally. The hs-TnT levels were determined with sand-
wich immunoassays using the Cobas Analytics e601 Im-
munoanalyzer (Roche Diagnostics, Mannheim, Germany)
according to the manufacturer’s instructions. According to
the manufacturer, the limit of the blank with this assay is
3 ng/l and the limit of detection is 5 ng/l. The coefﬁcient of
variation is <10% at 14 ng/l, the 99th percentile upper
reference limit for healthy subjects.
Statistical analyses. These analyses included the 14,897
patients who provided blood samples for the biomarker study
at randomization and also had available results of the evalu-
ated biomarkers. Demographics and other baseline charac-
teristics were summarized using frequencies for categorical
variables and median and 25th and 75th percentiles for
continuous variables. For tests of differences among groups,
the chi-square test was used for categorical variables and the
Kruskal-Wallis test was used for continuous variables.
Multivariable analysis of variance with natural logarithms
of hs-TnT as the response variable and categorized baseline
characteristics as the explanatory variables was used to
investigate the independent effect of each variable.
Geometric means, calculated by antilogs of the model-
adjusted means, were compared. Efﬁcacy analyses included
all randomized patients and included all events from
randomization until the efﬁcacy cutoff date (pre-deﬁned as
January 30, 2011). Bleeding analyses were “on treatment,”
including all randomized patients who received at least 1
dose of study drug, and included all events from receipt of
the study drug until 2 days after the last dose of the study
drug. The incidences of the different endpoints were
summarized in relation to randomized treatment, quartiles
of the hs-TnT levels, and CHA2DS2VASc and HAS-
BLED scores as outlined in the preceding text.The outcomes in relation to treatment and hs-TnT
subgroups were analyzed using a Cox proportional hazards
model, including treatment group, hs-TnT quartile group,
and treatment by hs-TnT interaction as covariates. The
estimated hazard ratios (HRs) were used to assess the
treatment effect in each of the subgroups, and the signiﬁ-
cance of the biomarker interacting with the effect of treat-
ment was judged by the signiﬁcance of the interaction
statistic. The outcomes in relation to hs-TnT quartiles were
evaluated both in a multivariable Cox proportional hazards
model and a model including randomized treatment and
CHA2DS2VASc score. The multivariable analyses included
established risk factors (age, sex, body mass index, smoking
status, systolic blood pressure, heart rate, AF type, diabetes,
heart failure, previous stroke/systemic embolism/transient
ischemic attack, hypertension, previous myocardial infarc-
tion, previous peripheral arterial disease/coronary artery
bypass graft/percutaneous coronary intervention, and treat-
ment at randomization with aspirin, an angiotensin-
converting enzyme inhibitor or angiotensin II receptor
blocker, or amiodarone for the major bleeding endpoint;
a history of anemia and a history of spontaneous or clinical
relevant bleeding were also included), randomized treat-
ment, region, use of warfarin within 7 days before ran-
domization, use of a statin medication within 30 days before
determination of the randomization score, and biomarkers
(cystatin C and N-terminal pro-brain natriuretic peptide
levels). The HRs and 95% conﬁdence intervals (CIs),
using the group with the lowest hs-TnT levels as reference,
were reported.
The increased discriminative value of hs-TnT was
investigated by estimating the difference in C statistics
between models with and without biomarkers as well as the
integrated discrimination improvement measure (IDI) as
described by Pencina et al. (18,19). In these analyses, an
occurrence/nonoccurrence of an event, respectively, during
the follow-up period was used as a binary response, and the
C value will be the same as the area under the receiver-
operating characteristic curve. The relative IDI was calcu-
lated to facilitate interpretation of the IDI (20). In addition,
continuous (category-free) net reclassiﬁcation improve-
ment (NRI) was analyzed as a measure of the probability
of better reclassiﬁcation minus the probability of worse
reclassiﬁcation with the new model. The NRI among events
and among nonevents as well as the total NRI were
analyzed.
Likelihood ratio tests were performed to evaluate whether
the global model ﬁt improved after the addition of hs-TnT.
Kaplan-Meier estimates of the cumulative hazard rate
were calculated and plotted. All event rates were reported per
100 patient-years of follow-up. All statistical tests were 2-
tailed and performed at the 0.05 signiﬁcance level. There
were no adjustments for multiple comparisons. The Clinical
Trials Section at Uppsala Clinical Research Center, Uppsala,
Sweden, conducted the statistical analyses using SAS soft-
ware version 9.3 (SAS Institute Inc., Cary, North Carolina).
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55Results
Baseline characteristics and distribution of hs-TnT
levels. The distribution of hs-TnT levels showed a mean
of 14.5 ng/l and a median of 11.0 ng/l (25th percentile:
7.5 ng/l; 75th percentile: 16.7 ng/l) in the total population
without any differences between the randomized treat-
ment groups. Thus, 93.5% of the patients had measurable
hs-TnT levels; 50% had levels >11.0 ng/l, and 25% had
levels >16.7 ng/l.
Baseline characteristics and medications according to
quartiles of hs-TnT are shown in Table 1. Age, male sex,
higher body mass index, diabetes mellitus, congestive heart
failure, permanent or persistent AF, prior vascular disease
(stroke, peripheral arterial disease, coronary artery disease),Table 1 Summary of Demographic and Baseline Characteristics Acc
High-Se
7.5 >7.5–
n 3,771 3,7
Age (yrs) 64.0 (58.0, 70.0) 70.0 (63
Male 2,027 (53.8) 2,352 (62
Weight (kg) 82.9 (70.0, 95.8) 82.0 (70
Permanent or persistent atrial ﬁbrillation 2,962 (78.5) 3,161 (84
Calculated CrCl (ml/min) 87.0 (68.8, 109.8) 76.7 (60
CHADS2 risk factors
CHF or LVEF 40% 1,066 (28.3) 1,160 (31
Hypertension 3,315 (87.9) 3,276 (87
75 yrs of age 472 (12.5) 989 (26
Diabetes mellitus 693 (18.4) 852 (22
Prior stroke or TIA 618 (16.4) 673 (18
CHA2DS2VASc risk factors
65–74 yrs of age 1,371 (36.4) 1,642 (43
Female 1,744 (46.2) 1,395 (37
Myocardial infarction 249 (6.6) 415 (11
Previous PCI/CABG 264 (7.0) 469 (12
Peripheral arterial disease 88 (2.3) 146 (3.
CHADS2 score
1 1,861 (49.4) 1,431 (38
2 1,194 (31.7) 1,358 (36
3 716 (19.0) 958 (25
CHA2DS2VASc score
1 627 (16.6) 329 (8.
2 1,082 (28.7) 885 (23
3 947 (25.1) 994 (26
4 644 (17.1) 821 (21
5 471 (12.5) 718 (19
Medications at randomization
Aspirin 1,073 (28.5) 1,103 (29
Warfarin 1,999 (53.2) 2,085 (55
ACE inhibitor or ARB 2,519 (66.8) 2,597 (69
Calcium-channel blocker 1,206 (32.0) 1,180 (31
Beta blocker 2,431 (64.5) 2,388 (63
Digoxin 904 (24.0) 1,081 (28
Values are median (25th percentile, 75th percentile) or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; CABG ¼ coronary artery
mellitus, previous stroke or transient ischemic attack; CHA2DS2VASc ¼ congestive heart failure, hyperte
vascular disease, 65 to 74 years of age, female; CHF ¼ congestive heart failure; CrCl ¼ creatinine cle
transient ischemic attack.and renal impairment had the strongest independent rela-
tionships to the hs-TnT level on multivariable analysis
(p < 0.001 for all). Except for hypertension, all risk factors
that constitute the CHADS2 and CHA2DS2VASc scores
were more common in patients with higher hs-TnT levels.
Accordingly, among patients with hs-TnT levels >16.7 ng/l,
83.6% had a CHA2DS2VASc score >2, in contrast to only
54.7% in patients with hs-TnT levels 7.5 ng/l.
hs-TnT levels in relation to outcome events. In this
substudy cohort, there were 397 stroke or systemic em-
bolism events (1.40%/year), 1,075 total deaths (3.69%/year),
547 cardiac deaths (1.88%/year), 150 myocardial infarc-
tions (0.52%/year), and 674 events of major bleeding
(2.61%/year).ording to High-Sensitivity Troponin T Level at Baseline
nsitivity Troponin T Level (ng/l)
p Value11.0 >11.0–16.7 >16.7
47 3,682 3,697
.0, 75.0) 72.0 (66.0, 77.0) 74.0 (67.0, 79.0) <0.0001
.8) 2,455 (66.7) 2,758 (74.6) <0.0001
.0, 95.0) 82.0 (70.0, 96.0) 82.0 (70.0, 96.0) 0.6862
.4) 3,224 (87.6) 3,294 (89.1) <0.0001
.9, 97.7) 70.3 (54.2, 89.4) 62.2 (46.8, 80.9) <0.0001
.0) 1,377 (37.4) 1,742 (47.1) <0.0001
.4) 3,225 (87.6) 3,222 (87.2) 0.7960
.4) 1,399 (38.0) 1,709 (46.2) <0.0001
.7) 945 (25.7) 1,189 (32.2) <0.0001
.0) 728 (19.8) 776 (21.0) <0.0001
.8) 1,507 (40.9) 1,319 (35.7) <0.0001
.2) 1,227 (33.3) 939 (25.4) <0.0001
.1) 545 (14.8) 705 (19.1) <0.0001
.5) 542 (14.7) 746 (20.2) <0.0001
9) 203 (5.5) 287 (7.8) <0.0001
.2) 1,042 (28.3) 723 (19.6) <0.0001
.2) 1,410 (38.3) 1,412 (38.2)
.6) 1,230 (33.4) 1,562 (42.3)
8) 200 (5.4) 143 (3.9) <0.0001
.6) 669 (18.2) 463 (12.5)
.5) 962 (26.1) 968 (26.2)
.9) 912 (24.8) 926 (25.0)
.2) 939 (25.5) 1,197 (32.4)
.4) 1,166 (31.7) 1,262 (34.1) <0.0001
.7) 1,961 (53.4) 1,959 (53.0) 0.0615
.3) 2,622 (71.2) 2,802 (75.8) <0.0001
.5) 1,144 (31.1) 1,023 (27.7) 0.0002
.7) 2,310 (62.7) 2,288 (61.9) 0.1056
.8) 1,316 (35.7) 1,528 (41.3) <0.0001
bypass graft; CHADS2 ¼ congestive heart failure, hypertension, 75 years of age and older, diabetes
nsion, 75 years of age and older, diabetes mellitus, previous stroke or transient ischemic attack,
arance; LVEF ¼ left ventricular ejection fraction; PCI ¼ percutaneous coronary intervention; TIA ¼
Figure 1 Efﬁcacy of Apixaban Relative to Warfarin in Relation to High-Sensitivity Troponin T Level at Baseline
Cox proportional hazards model with biomarker level, treatment, and interaction between treatment and biomarker level as covariates. CI ¼ conﬁdence interval; CS ¼ clinically
signiﬁcant; HR ¼ hazard ratio.
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56When comparing the outcomes in relation to the
randomized treatments, there was no signiﬁcant interaction
with the hs-TnT levels at baseline (Fig. 1). Thus, there were
consistent reductions in rates of stroke, hemorrhagic stroke,
total mortality, composites of these events, and major
bleeding across the range of hs-TnT levels (all interaction
p values >0.10). When evaluating the association between
hs-TnT levels and outcomes, the randomized treatment
groups were therefore combined and adjusted for in the
multivariable analyses.
Higher hs-TnT levels were strongly and signiﬁcantly
associated with a higher rate of all outcome events even after
adjustment for baseline characteristics and indicators of
myocardial and renal dysfunction in the multivariable model
(Fig. 2). In regard to stroke, the risk was signiﬁcantly
higher in patients with hs-TnT levels >11.0 ng/l and
almost doubled in the group with hs-TnT levels >16.7 ng/l
as compared with the group with hs-TnT levels <7.5 ng/l
with an adjusted HR of 1.94 (95% CI: 1.35 to 2.78;p ¼ 0.0010 for effect of hs-TnT). This increased risk of
stroke was driven mainly by higher rates of ischemic stroke.
Cardiac mortality increased gradually with higher hs-TnT
levels, reaching an adjusted HR of 4.31 (95% CI: 2.91 to
6.37; p < 0.0001) in the group with hs-TnT levels >16.7
ng/l versus the lowest quartile hs-TnT group. Despite the
overall low event rates, there was a similar association
between hs-TnT levels and subsequent myocardial infarc-
tion, with a signiﬁcantly raised risk with higher hs-TnT
levels and an adjusted HR of 5.52 (95% CI: 2.56 to
11.92) in the group with hs-TnT levels >16.7 ng/l versus
the lowest quartile hs-TnT group. The rates of the
composite of the individual events showed correspondingly
strongly signiﬁcant associations with increasing hs-TnT
levels. Also, the rate of major bleeding displayed a gra-
dual relationship to increased hs-TnT levels and an ad-
justed HR of 1.91 (95% CI: 1.43 to 2.56) in the group with
the highest versus lowest quartile hs-TnT group. Similar
results were obtained when adjusting for the HAS-BLED
Figure 2 The Relationship Between High-Sensitivity Troponin T Level at Baseline and Outcomes
Cox proportional hazards model adjusted for established risk factors (age, sex, body mass index, smoking status, systolic blood pressure, heart rate, type of atrial ﬁbrillation,
diabetes, heart failure, previous stroke/systemic embolism/transient ischemic attack, hypertension, previous myocardial infarction, previous peripheral arterial disease/
coronary artery bypass graft/percutaneous coronary intervention, and treatment at randomization with aspirin, an angiotensin-converting enzyme inhibitor or angiotensin II
receptor blocker, or amiodarone for the major bleeding endpoint; a history of anemia and a history of spontaneous or clinical relevant bleeding were also included), randomized
treatment, region, use of warfarin within 7 days before randomization, use of statin medication within 30 days before determination of the randomization score, and biomarkers
(cystatin C and N-terminal pro-brain natriuretic peptide). Q = quartile; other abbreviations as in Figure 1.
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57score (results not shown). As illustrated in the Kaplan-
Meier plots (Figs. 3A to 3C), the associations between
hs-TnT levels at baseline and the risk of subsequent events
remained stable over time.
hs-TnT level and CHA2DS2VASc score. Annual rates of
stroke or systemic embolism according to hs-TnT level and
CHA2DS2VASc score are illustrated in Figure 4. The rate
increased with both increasing CHA2DS2VASc score and
higher hs-TnT level. The highest annual rate of stroke and
systemic embolism, 2%/year, was found in the group with
a CHA2DS2VASc score >4 or hs-TnT level >11.0 ng/l
compared with an average annual rate of <0.4% in the group
with a CHA2DS2VASc score 2 and hs-TnT level 11.0
ng/l (Fig. 4A). Thus, the hs-TnT level and CHA2DS2-
VASc score provided statistically signiﬁcant independent
prognostic information; the C statistic was 0.620 (95% CI:0.592 to 0.647) for the CHA2DS2VASc score alone and not
signiﬁcantly different from 0.591 (95% CI: 0.564 to 0.619)
(p ¼ 0.1080) for the hs-TnT level alone and increased
signiﬁcantly to 0.635 (95% CI: 0.609 to 0.661), corresponding
to a relative IDI improvement of 23.0% (p ¼ 0.0010) by
adding the hs-TnT level to the CHA2DS2VASc score.
There was a signiﬁcant improvement in reclassiﬁcation by
addition of the hs-TnT level based on continuous NRI
analyses (27.4% [95% CI: 17.7% to 37.1%; p < 0.0001)
for stroke or systemic embolism, mainly due to events
contributing (23.9%).
For cardiac mortality, increasing hs-TnT level had
a larger impact on outcomes than the CHA2DS2VASc
score (Fig. 4B), with a C statistic of 0.592 (95% CI: 0.567
to 0.616) for the CHA2DS2VASc score alone and signif-
icantly higher at 0.699 (95% CI: 0.678 to 0.719)
A B
C
Figure 3 Cumulative Hazard Rates According to High-Sensitivity Troponin T Quartiles
Cumulative hazard rates for (A) the primary outcome (stroke or systemic embolism [SEE]), (B) cardiac death, and (C) major bleeding by high-sensitivity (hs) troponin T level
at baseline.
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58(p < 0.0001) for the hs-TnT level alone. The C statistic
increased signiﬁcantly to 0.711 (95% CI: 0.690 to 0.733),
corresponding to a relative IDI improvement of 314.9%
(p < 0.0001) and NRI of 56.6% (95% CI: 48.4% to
64.8%; p < 0.0001) by adding the hs-TnT level to the
CHA2DS2VASc score. Accordingly, for the composite
of ischemic events and mortality, an increasing hs-TnTlevel had a stronger association with outcomes than the
CHA2DS2VASc score, with a C statistic of 0.597 for the
CHA2DS2VASc score alone, which was signiﬁcantly
higher for the hs-TnT level alone at 0.660 (95% CI: 0.642
to 0.678) (p < 0.0001) and increasing to 0.675 (95%
CI: 0.657 to 0.693), corresponding to a relative IDI
improvement of 207.9% (p < 0.0001) by adding the
Figure 4 High-Sensitivity Troponin T Quartiles in Relation to the CHA2DS2-VASc Score
Annual event rates for (A) stroke or systemic embolism, (B) cardiac death, and (C) major bleeding in relation to levels of high-sensitivity (hs) troponin T and the CHA2DS2-VASc
risk score stratiﬁed as 0 to 1/2/3/4/5. The numbers of patients in the rising hs troponin T quartiles with a CHA2DS2-VASc score of 0 to 1 were 625, 325, 205, and 143; with
a score of 2 were 1,137, 805, 685, and 472; with a score of 3 were 1,039, 888, 947, and 994; with a score of 4 were 713, 750, 939, and 898; and with a score 5 were 560,
662, 909, and 1,195, respectively. CHA2DS2-VASc ¼ congestive heart failure, hypertension, 75 years of age and older, diabetes mellitus, previous stroke or transient ischemic
attack, vascular disease, 65 to 74 years of age, female.
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59hs-TnT level to the CHA2DS2VASc score. Also, regard-
ing major bleeding, there was a consistent increase with
both increasing hs-TnT and CHA2DS2VASc scoregroups (Fig. 4C). The C statistic was 0.591 for the
CHA2DS2VASc score alone, which was signiﬁcantly
higher than 0.617 (95% CI: 0.596 to 0.637) (p ¼ 0.0319)
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60for the hs-TnT level alone, and increased to 0.629 (95%
CI: 0.609 to 0.650), corresponding to a relative IDI
improvement of 84% (p < 0.0001) by adding the hs-TnT
level to the CHA2DS2VASc score.
For all outcomes, likelihood ratio tests showed that the
global model ﬁt improved after the addition of hs-TnT level
(all p < 0.001).
Discussion
The present study showed that hs-TnT levels can be detected
in almost all patients (93.5%) with AF and at least 1 clinical
risk factor for stroke. The level of hs-TnTwas related tomany
clinical risk factors, such as age, male sex, higher body mass
index, diabetes mellitus, prior vascular disease, permanent
or persistent AF, and indicators of myocardial and renal
dysfunction. Even after adjustment for these factors, the level
of hs-TnT carried strong prognostic information with a
gradual increase in the risk of stroke, cardiac and total
death, myocardial infarction, and major bleeding with rising
hs-TnT levels. An increased risk of stroke was present at
hs-TnT levels above the median (11.0 ng/l), whereas raised
risks of myocardial infarction, cardiac and total mortality,
and major bleeding were seen at even lower hs-TnT levels
(>7.5 ng/l). In regard to cardiac mortality, myocardial
infarction, and major bleeding, the hs-TnT level alone
provided better prognostic information than did the
CHA2DS2VASc risk score. The combination of the hs-TnT
level with the CHA2DS2VASc risk score, however, allowed
improved identiﬁcation of patients at lower and higher risk of
stroke compared with either indicator alone. There was no
interaction between risk stratiﬁcation by hs-TnT level and the
superior efﬁcacy and safety of apixaban as compared with
warfarin. Therefore, there was a larger absolute reduction in
stroke, mortality, and major bleeding in patients at higher risk
(e.g., as identiﬁed by higher hs-TnT levels).
The present results support the independent prognostic
value of troponin I levels concerning the risk of stroke,
mortality, composite ischemic events, and major bleeding
in patients with AF, as recently shown in the RE-LY
(Randomized Evaluation of Long Term Anticoagulant
Therapy) trial (7). The considerably larger number of
patients and the more sensitive troponin assay in the present
study (n ¼ 14,897) as compared with the RE-LY biomarker
study (n ¼ 6,189) provided a greater discriminatory power in
regard to the relationship between hs-TnT levels and indi-
vidual outcome events and also in the comparison and
combination with the CHA2DS2VASc score. In regard to
stroke, the hs-TnT level and CHA2DS2VASc score
provided complementary information, with the lowest risk in
those having both a low hs-TnT level (<11.0 ng/l) and
a low CHA2DS2VASc score (2). It is noteworthy that the
determination of hs-TnT level among patients with a low
CHA2DS2VASc score (2) can identify patients at risks
for stroke and major bleeding similar to those among
patients with CHA2DS2VASc scores >3. Likewise, it isremarkable that, concerning stroke, the CHA2DS2VASc
score provides further risk stratiﬁcation within all hs-TnT
subgroups. This information will therefore immediately be
clinically useful because it allows for the identiﬁcation of
patients with low CHA2DS2VASc scores who nevertheless
are at high risk for stroke. This should improve therapeutic
decision making related to oral anticoagulation.
Concerning cardiac mortality, myocardial infarction, and
even major bleeding, the hs-TnT level provided more
prognostic information than did the CHA2DS2VASc score.
This emphasizes that the clinical characteristics included in
the CHA2DS2VASc risk score have been identiﬁed to
provide information on the risk of stroke but only contribute
limited information on the risk of other events of major
clinical importance for patients with AF. By the inclusion of
hs-TnT level in the risk-stratiﬁcation process, additional
information on the risk of cardiac and total mortality and
myocardial infarction and better prognostication of the risk
of bleeding will be provided. This information should
therefore also be immediately useful in decision making
concerning oral anticoagulants and even other medical
treatments for individual patients with AF.
Consistent results from 2 large-scale prospective trials,
together including 21,081 patients, provide deﬁnitive
evidence for the incremental prognostic value of hs-TnT
levels for stroke, cardiac and total death, other ischemic
events, and major bleeding in patients with AF (3,4,7). The
independent prognostic value of the hs-TnT levels is also
validated by similar ﬁndings in healthy elderly subjects,
patients with acute and chronic atherosclerotic diseases, and
patients with congestive heart failure (10,11,13–16). The
underlying mechanisms for this independent relationship are
probably multifactorial because the level of hs-TnT is related
to aging and tissue vulnerability, myocardial necrosis and
apoptosis, myocardial stress (e.g., due to increased or variable
heart rates), myocardial dysfunction with variations in
atrial and ventricular volume and pressure load, and episodes
of myocardial ischemia (e.g., due to microembolism) (2,21–
24). There might also be an association with underlying
inﬂammatory and ﬁbrotic processes, including endothelial
dysfunction and a hypercoagulable state, that might
contribute to both AF and the risk of thromboembolism
(25,26). However, even without a complete understanding
of the underlying mechanisms, the ﬁrm evidence of the
incremental prognostic value of hs-TnT for risk stratiﬁca-
tion and the availability of this test in almost every
hospital worldwide should make it a very attractive tool to
include as decision support for selection of treatment in
patients with AF.
Study limitations. All patients were treated with oral
anticoagulation, which impairs the opportunity to provide
clear recommendations on which patients might beneﬁt, or
not, from this type of treatment. Also, our results were based
on a clinical trial population, which will be somewhat
different and generally at lower risk than an unselected
clinical patient population.
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In patients with AF treated with oral anticoagulation, the
level of hs-TnT, even within the normal range, is gradually
and independently related to the risk of stroke, myocardial
infarction, cardiac and total death, and major bleeding. The
combination of the hs-TnT level and the CHA2DS2VASc
risk score allows improved and safer identiﬁcation of
patients both at very low risk and at higher risk for stroke,
whereas the hs-TnT level alone carries most of the infor-
mation on the risk of other ischemic events, cardiac mortality,
and bleeding. The beneﬁts of apixaban as compared with
warfarin are consistent regardless of the hs-TnT level. The
combination of the hs-TnT level and the CHA2DS2VASc
risk score might provide improved decision support con-
cerning anticoagulant and other treatments in patients
with AF.
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